Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction

Smita I. Negi, Euy Myoung Jeong, Irfan Shukrullah, Emir Veleder, Dean P. Jones, Tai Hwang M. Fan, Sudhahar Varadarajan, Sergei M. Danilov, Tohru Fukai, Samuel C. Dudley

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Animal models have suggested a role of renin-Angiotensin system (RAS) activation and subsequent cardiac oxidation in heart failure with preserved ejection fraction (HFpEF). Nevertheless, RAS blockade has failed to show efficacy in treatment of HFpEF. We evaluated the role of RAS activation and subsequent systemic oxidation in HFpEF. Oxidative stress markers were compared in 50 subjects with and without early HFpEF. Derivatives of reactive oxidative metabolites (DROMs), F2-isoprostanes (IsoPs), and ratios of oxidized to reduced glutathione (E h GSH) and cysteine (E h CyS) were measured. Angiotensin converting enzyme (ACE) levels and activity were measured. On univariate analysis, HFpEF was associated with male sex (p = 0.04), higher body mass index (BMI) (p = 0.003), less oxidized E h CyS (p = 0.001), lower DROMs (p = 0.02), and lower IsoP (p = 0.03). Higher BMI (OR: 1.3; 95% CI: 1.1-1.6) and less oxidized E h CyS (OR: 1.2; 95% CI: 1.1-1.4) maintained associations with HFpEF on multivariate analysis. Though ACE levels were higher in early HFpEF (OR: 1.09; 95% CI: 1.01-1.05), ACE activity was similar to that in controls. HFpEF is not associated with significant systemic RAS activation or oxidative stress. This may explain the failure of RAS inhibitors to alter outcomes in HFpEF.

Original languageEnglish (US)
Article number825027
JournalBioMed Research International
Volume2015
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Oxidative stress
Angiotensins
Renin
Oxidative Stress
Heart Failure
Chemical activation
Renin-Angiotensin System
Peptidyl-Dipeptidase A
Cysteine
Metabolites
Body Mass Index
F2-Isoprostanes
Derivatives
Oxidation
Enzyme activity
Treatment Failure
Glutathione
Animals
Multivariate Analysis
Animal Models

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Negi, S. I., Jeong, E. M., Shukrullah, I., Veleder, E., Jones, D. P., Fan, T. H. M., ... Dudley, S. C. (2015). Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction. BioMed Research International, 2015, [825027]. https://doi.org/10.1155/2015/825027

Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction. / Negi, Smita I.; Jeong, Euy Myoung; Shukrullah, Irfan; Veleder, Emir; Jones, Dean P.; Fan, Tai Hwang M.; Varadarajan, Sudhahar; Danilov, Sergei M.; Fukai, Tohru; Dudley, Samuel C.

In: BioMed Research International, Vol. 2015, 825027, 01.01.2015.

Research output: Contribution to journalArticle

Negi, Smita I. ; Jeong, Euy Myoung ; Shukrullah, Irfan ; Veleder, Emir ; Jones, Dean P. ; Fan, Tai Hwang M. ; Varadarajan, Sudhahar ; Danilov, Sergei M. ; Fukai, Tohru ; Dudley, Samuel C. / Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction. In: BioMed Research International. 2015 ; Vol. 2015.
@article{c3b64262cf6344b0bb3bb0e678fa20f8,
title = "Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction",
abstract = "Animal models have suggested a role of renin-Angiotensin system (RAS) activation and subsequent cardiac oxidation in heart failure with preserved ejection fraction (HFpEF). Nevertheless, RAS blockade has failed to show efficacy in treatment of HFpEF. We evaluated the role of RAS activation and subsequent systemic oxidation in HFpEF. Oxidative stress markers were compared in 50 subjects with and without early HFpEF. Derivatives of reactive oxidative metabolites (DROMs), F2-isoprostanes (IsoPs), and ratios of oxidized to reduced glutathione (E h GSH) and cysteine (E h CyS) were measured. Angiotensin converting enzyme (ACE) levels and activity were measured. On univariate analysis, HFpEF was associated with male sex (p = 0.04), higher body mass index (BMI) (p = 0.003), less oxidized E h CyS (p = 0.001), lower DROMs (p = 0.02), and lower IsoP (p = 0.03). Higher BMI (OR: 1.3; 95{\%} CI: 1.1-1.6) and less oxidized E h CyS (OR: 1.2; 95{\%} CI: 1.1-1.4) maintained associations with HFpEF on multivariate analysis. Though ACE levels were higher in early HFpEF (OR: 1.09; 95{\%} CI: 1.01-1.05), ACE activity was similar to that in controls. HFpEF is not associated with significant systemic RAS activation or oxidative stress. This may explain the failure of RAS inhibitors to alter outcomes in HFpEF.",
author = "Negi, {Smita I.} and Jeong, {Euy Myoung} and Irfan Shukrullah and Emir Veleder and Jones, {Dean P.} and Fan, {Tai Hwang M.} and Sudhahar Varadarajan and Danilov, {Sergei M.} and Tohru Fukai and Dudley, {Samuel C.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1155/2015/825027",
language = "English (US)",
volume = "2015",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction

AU - Negi, Smita I.

AU - Jeong, Euy Myoung

AU - Shukrullah, Irfan

AU - Veleder, Emir

AU - Jones, Dean P.

AU - Fan, Tai Hwang M.

AU - Varadarajan, Sudhahar

AU - Danilov, Sergei M.

AU - Fukai, Tohru

AU - Dudley, Samuel C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Animal models have suggested a role of renin-Angiotensin system (RAS) activation and subsequent cardiac oxidation in heart failure with preserved ejection fraction (HFpEF). Nevertheless, RAS blockade has failed to show efficacy in treatment of HFpEF. We evaluated the role of RAS activation and subsequent systemic oxidation in HFpEF. Oxidative stress markers were compared in 50 subjects with and without early HFpEF. Derivatives of reactive oxidative metabolites (DROMs), F2-isoprostanes (IsoPs), and ratios of oxidized to reduced glutathione (E h GSH) and cysteine (E h CyS) were measured. Angiotensin converting enzyme (ACE) levels and activity were measured. On univariate analysis, HFpEF was associated with male sex (p = 0.04), higher body mass index (BMI) (p = 0.003), less oxidized E h CyS (p = 0.001), lower DROMs (p = 0.02), and lower IsoP (p = 0.03). Higher BMI (OR: 1.3; 95% CI: 1.1-1.6) and less oxidized E h CyS (OR: 1.2; 95% CI: 1.1-1.4) maintained associations with HFpEF on multivariate analysis. Though ACE levels were higher in early HFpEF (OR: 1.09; 95% CI: 1.01-1.05), ACE activity was similar to that in controls. HFpEF is not associated with significant systemic RAS activation or oxidative stress. This may explain the failure of RAS inhibitors to alter outcomes in HFpEF.

AB - Animal models have suggested a role of renin-Angiotensin system (RAS) activation and subsequent cardiac oxidation in heart failure with preserved ejection fraction (HFpEF). Nevertheless, RAS blockade has failed to show efficacy in treatment of HFpEF. We evaluated the role of RAS activation and subsequent systemic oxidation in HFpEF. Oxidative stress markers were compared in 50 subjects with and without early HFpEF. Derivatives of reactive oxidative metabolites (DROMs), F2-isoprostanes (IsoPs), and ratios of oxidized to reduced glutathione (E h GSH) and cysteine (E h CyS) were measured. Angiotensin converting enzyme (ACE) levels and activity were measured. On univariate analysis, HFpEF was associated with male sex (p = 0.04), higher body mass index (BMI) (p = 0.003), less oxidized E h CyS (p = 0.001), lower DROMs (p = 0.02), and lower IsoP (p = 0.03). Higher BMI (OR: 1.3; 95% CI: 1.1-1.6) and less oxidized E h CyS (OR: 1.2; 95% CI: 1.1-1.4) maintained associations with HFpEF on multivariate analysis. Though ACE levels were higher in early HFpEF (OR: 1.09; 95% CI: 1.01-1.05), ACE activity was similar to that in controls. HFpEF is not associated with significant systemic RAS activation or oxidative stress. This may explain the failure of RAS inhibitors to alter outcomes in HFpEF.

UR - http://www.scopus.com/inward/record.url?scp=84945270378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945270378&partnerID=8YFLogxK

U2 - 10.1155/2015/825027

DO - 10.1155/2015/825027

M3 - Article

VL - 2015

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 825027

ER -